Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Small Molecules
Filter     Order     Display # 
Date Item Title
14 Apr 2006 MAA Submission for Candin Antifungal Agent Micafungin in EU
13 Apr 2006 Pharmagap Confirms Efficacy Of Its Lead Drug Compound To Treat Chemo-Resistant Colorectal Cancer
12 Apr 2006 Lilly Announces Preliminary Coronary and Breast Cancer Results from Raloxifene Use for The Heart (RUTH) Study
12 Apr 2006 FDA Grants Accentia Biopharmaceuticals Fast Track Status for SinuNase(TM); First and Only Product under Development for Chronic Sinusitis to Receive Fast Track Status from FDA
11 Apr 2006 European Regulatory Committee Recommends Orphan Medicinal Product Designation for Amicus Therapeutics' Amigal(TM) for Fabry Disease
11 Apr 2006 Chiron Announces Initiation of Phase 1 Trial for CHIR-265 In Melanoma; Clinical Testing of Novel Oncology Compound Begins in Patients with Skin Cancer
11 Apr 2006 Prometic Initiates Patient Enrollment For Its Anemia Drug PBI-1402 Phase IB/II Clinical Trial
11 Apr 2006 Enrollment Passes Midpoint in Voyager Pharmaceutical Corporation's Phase III Alzheimer's Trial Ahead of Schedule
11 Apr 2006 BioLineRx Initiates Phase 1 Clinical Trials of BL-1020, First in Class Small Molecule for the Treatment Of Schizophrenia
10 Apr 2006 Quigley to Commence Human Testing of Its QR-333 Topical Diabetic Peripheral Neuropathy Investigational New Drug; FDA Finalizes review cycle and gives Quigley go ahead to begin Phase II studies under IND number 67,168
10 Apr 2006 Myogen Reports Positive Top Line Results for Second Ambrisentan Pivotal Phase 3 Trial in Pulmonary Arterial Hypertension; ARIES-1 Confirms Efficacy and Safety Results Observed in ARIES-2; NDA Submission Expected in Fourth Quarter
10 Apr 2006 Novartis completes submissions in US and Europe for Glivec® as treatment for four rare types of cancer
10 Apr 2006 Somaxon Pharmaceuticals Announces Positive Phase 3 Results with SILENOR™ for the Treatment of Adults with Chronic Insomnia
09 Apr 2006 Kissei Pharmaceutical to License KGA, Diabetes Drug Candidate, to GlaxoSmithKline
08 Apr 2006 REVLIMID(R) Marketing Authorization Application Accepted by EMEA for Review
08 Apr 2006 CombinatoRx Reports Preliminary Data for Drug Candidate CRx-119 in an Exploratory Immuno-Inflammatory Disease Model; Does Not Meet Primary Endpoint of Reduction of C-Reactive Protein, Analysis of Cytokines is Ongoing
07 Apr 2006 AVELOX(R) Monotherapy as Effective as High-Dose Levofloxacin and Ceftriaxone Combination Therapy in Treating Patients With Severe Community-Acquired Pneumonia
07 Apr 2006 Boehringer Ingelheim’s Sifrol®/ Mirapexin® (pramipexole) is first treatment for Restless Legs Syndrome (RLS) to become approved throughout the European Union (EU)
07 Apr 2006 Phase III Data on Fesoterodine to be Presented at the EAU Congress
07 Apr 2006 SCHWARZ PHARMA to present Lacosamide Data in Neuropathic Pain on the AAN Congress
07 Apr 2006 New Data Show Cialis® (tadalafil) is Effective in Treating Erectile Dysfunction Caused by Traumatic Spinal Cord Injury
07 Apr 2006 Medicure Reports Positive POD 90 Results From The MEND-CABG Study
07 Apr 2006 Reata Announces RTA 402 Entering Clinical Development
06 Apr 2006 TopoTarget and CuraGen present encouraging new data on PXD101 at the AACR 97th Annual Meeting
06 Apr 2006 ARIXTRA(R) Significantly Reduced Major Bleeding Compared to LOVENOX(R) in a Study of Patients With Acute Coronary Syndromes
06 Apr 2006 Cerexa Announces Completion of Enrollment in Ceftaroline Phase 2 Trial
06 Apr 2006 Phase II data for FTY720 shows sustained efficacy and good tolerability over 18 months in patients with relapsing multiple sclerosis (MS)
06 Apr 2006 Teva Announces That Higher Dose Of Copaxone® Showed Increased Efficacy In Multiple Sclerosis (Ms)
06 Apr 2006 Othera Pharmaceuticals and the National Eye Institute Collaborate in Dry AMD Study; A Phase II Study of OT-551 Antioxidant Eye Drop in Participants with Bilateral Geographic Atrophy Associated with Age-Related Macular Degeneration
06 Apr 2006 Preclinical Data Demonstrate Gemin X Compound GX15-070 Induces Apoptosis in Mantle Cell Lymphoma and Exhibits Synergy with Velcade; Data Presented at 97th Annual Meeting of the American Association for Cancer Research (AACR)
06 Apr 2006 New Research Proves RTA 402 is Potent Inhibitor of NF-κB in Cancer Cells Through Inhibition of IKK
06 Apr 2006 TargeGen Presents Data for TG100801, a Topically Applied Compound for the Potential Treatment of Major Eye Diseases Including Macular Degeneration
05 Apr 2006 Bioenvision's Evoltra(R) Achieves High Response Rates in Adult AML; New Interim Data Presented from Phase I/II Clinical Study
05 Apr 2006 New data suggest pramipexole can significantly improve quality of life (QoL) for people with Restless Legs Syndrome (RLS)
05 Apr 2006 Neurocrine Announces Peer-Reviewed Publication of Indiplon Mechanism of Action
05 Apr 2006 OSI Pharmaceuticals IGF-1R Inhibitor Program Featured in 97th Annual Meeting of the American Association of Cancer Research Media Program
05 Apr 2006 Vertex Pharmaceuticals Announces Initiation of Phase II Development Program for Aurora Kinase Inhibitor MK-0457 (VX-680)
05 Apr 2006 Threshold Pharmaceuticals Completes Enrollment in Phase 3 Study for the Treatment of Benign Prostatic Hyperplasia
05 Apr 2006 Vion Presents Preclinical Data on Cloretazine(R) (VNP40101M), a Hypoxia-Selective Compound (VNP40541) and Hydrazones at AACR Meeting
05 Apr 2006 Ascenta Therapeutics Novel MDM2-p53 Inhibitors Demonstrate Preclinical Single Agent Efficacy in Multiple Tumor Models
05 Apr 2006 AV-412 Preclinical Efficacy Data Presented at AACR 2006
05 Apr 2006 Interim Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 3 Trial
05 Apr 2006 CytRx Completes Enrollment in Phase IIa Clinical Trial for ALS; Final Phase IIa Data Expected to be Reported in Third Quarter 2006
05 Apr 2006 ArQule Reports Encouraging Phase 1 Monotherapy Data among Patients Treated with ARQ 501; Findings Highlighted in Late-Breaking Session at 97th Annual AACR Meeting
04 Apr 2006 Interim Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 3 Trial
04 Apr 2006 Æterna Zentaris Discloses Preclinical Results on Various Drug Candidates at the American Association for Cancer Research (AACR) Meeting in Washington
04 Apr 2006 Sepracor Announces Publication of LUNESTA(TM) Insomnia-Depression Study in Biological Psychiatry
04 Apr 2006 Cephalon Oncology Compound Lestaurtinib (CEP-701) Granted Orphan Drug Designation for Acute Myeloid Leukemia
04 Apr 2006 Avanir's Neurodex Nda Accepted With Priority Review For Involuntary Emotional Expression Disorder
04 Apr 2006 Sunesis Presents Data on Anti-Cancer Compound SNS-032 at American Association for Cancer Research Meeting
 
<< Start < Prev 101 102 103 104 105 106 107 108 109 110 Next > End >>
Results 5251 - 5300 of 5705

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics